October 9, 2014
CTI Announces Community Research to Become CTI Clinical Research Center
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ October 9, 2014]
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces that Community Research, acquired by CTI earlier this year, will change its name to CTI Clinical Research Center (CTI CRC).
“This change from Community Research to CTI CRC is a way to consolidate our company’s brand into a single, cohesive presence in the industry,” according to Timothy Schroeder, CEO. “We have maintained all Community Research associates and sponsors since they joined CTI, and we look forward to maximizing our full multi-national capabilities to benefit all of the sponsors and patients we serve.”
CTI has been working for over fifteen years in the drug development industry, specializing in clinical research programs involving critically ill patient populations, and has more than 20 offices worldwide to serve more than 80 pharmaceutical, biotechnology, and medical device clients.
About CTI Clinical Research Center
CTI Clinical Research Center is a dedicated, multi-specialty clinical research site with three locations throughout Greater Cincinnati, Ohio. The site conducts 40-60 phase I-IV clinical trials annually in a variety of therapeutic indications, including internal medicine, dermatology, psychiatry, and sleep disorders, as well as trials in healthy volunteers. CTI CRC operates a hospital-based, 60 bed residential phase I facility, which can accommodate drug and device trials, and has a special emphasis on first-in-human studies in various patient populations. The site has completed over 700 clinical trials in its lifetime.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.